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INTRODUCTION
Approximately one-third of patients with hepatocellular 
carcinoma (HCC) are diagnosed at an advanced stage with 
major portal vein (PV) tumor invasion.1 The expected prog-
nosis in such cases is typically poor despite the administra-
tion of optimal systemic therapy according to the practice 
guidelines.2 Sorafenib or lenvatinib is now an approved oral 
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multi-kinase inhibitor for prolonging the overall survival 
(OS) of patients with advanced-stage HCC. However, data 
supporting the survival benefits of molecular-targeted agents 
among patients with advanced-stage HCC with major PV in-
vasion are still limited.3
 Therefore, diverse treatment approaches, including a 
combination of various loco-regional therapies (LRT) and/
or systemic treatments, including transarterial chemoembo-
lization (TACE) plus radiotherapy (RT), tremelimumab with 
ablation, liver-directed concurrent chemoradiotherapy (LD-
CCRT) plus sequential sorafenib, and transarterial radio-
embolization (TARE) in combination with sorafenib, have 
been attempted in a concurrent or sequential manner.4-8 
Among these, TARE with Yttrium‐90 (Y-90) microspheres 
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has gained increasing acceptance as an alternative to TACE 
over the past decade and has become an increasingly popular 
treatment option owing to an increased and durable response 
and better tolerability.9 However, TARE is contraindicated in 
patients with an excessive lung shunt fraction (LSF).10 Here-
in, we report a case of advanced-stage HCC in which a tumor 
with high LSF was initially treated with LD-CCRT, which 
was subsequently delivered after confirmation of decreased 
lung shunting, leading to a complete response.
CASE REPORT
1. Clinical finding
A 55-year-old man presented with a large liver mass inci-
dentally detected on ultrasonography screening at another 
hospital. Although he uses to consume 2-3 bottles of beer per 
week, he did not have any underlying liver disease. There 
were no associated symptoms or remarkable findings on 
physical examination. The initial laboratory findings were as 
follows: white blood cell count, 5,670/µL; hemoglobin, 
14.5 g/dL; platelet count, 175,000/µL; total bilirubin, 0.9 mg/
dL; albumin, 4.9 g/dL; prothrombin time-international nor-
malized ratio, 1.09; aspartate aminotransferase, 142 U/L; and 
alanine aminotransferase, 157 U/L. Both hepatitis B surface 
antigen and anti-hepatitis C virus antibody were negative. 
The level of alpha-fetoprotein (AFP) was 4,868 ng/mL, and 
protein induced by the absence of vitamin K or antagonist-II 
(PIVKA-II) level was 27,544 mAU/mL. Liver function was 
preserved with a Child-Pugh score of 5 and the Eastern Co-
operative Oncology Group performance status was 1.
2. Imaging findings
Initial liver dynamic magnetic resonance imaging (MRI) 
revealed a 10.5 cm large tumor diagnosed as HCC with typi-
cal radiological features including hypervascularity in the ar-
terial phase and washout in the portal and delayed phases, at 
Figure 1. Initial liver dynamic magnetic resonance imaging findings. A single 10.5 cm-sized mass in segment VI showed enhancement in the 
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segment S6 (Fig. 1). Tumor thrombosis was observed in the 
right hepatic vein and the right anterior PV. Chest computed 
tomography (CT) revealed no evidence of hematogenous 
lung metastasis or lymph node enlargement.
3. Diagnosis and treatment
The patient was diagnosed with advanced stage HCC 
(BCLC, stage C; modified Union for International Cancer 
Control T3N0M0, stage III) without liver biopsy, based on 
typical imaging findings. First, we planned TARE with Yttri-
um-90; however, lung scintigraphy using technetium-99m-
labeled albumin macroaggregates (MAA-99mTc) revealed an 
intense radiotracer in the bilateral lung field, with an LSF of 
61.59% (Fig. 2A). Since the patient was at high risk of exces-
sive pulmonary irradiation after TARE, we planned LD-
CCRT as an alternative. The major aims of LD-CCRT were 
to reduce not only the tumor burden but also the LSF. 
A total of 75 Gy was prescribed in 25 fractions of 3.0 Gy 
over 5 weeks using a 10-megavolt linear accelerator. It was 
intended to deliver 95% of the prescribed dose encompass-
ing the planning target volume around the clinical target vol-
ume. Concurrent continuous-infusion hepatic arterial 5-flu-
orouracil (at a dose of 500 mg/day) was delivered during the 
first and fifth weeks of RT through a percutaneous hepatic 
arterial catheter (Chemoport), implanted at the time of ini-
tial hepatic arterial angiography. 
Three weeks after the completion of LD-CCRT, a response 
evaluation using CT was performed, which showed that the 
main tumor size had decreased from 10.5 cm to 8 cm and 
right PV thrombosis was not obvious (Fig. 3A). To deter-
mine whether TARE is eligible as a subsequent treatment 
modality, technetium-99m labeled MAA was employed 
again, revealing a markedly decreased LSF of 12.15% (Fig. 2B). 
Thus, based on a multi-disciplinary approach, TARE was 
subsequently performed to treat the remnant tumor 6 weeks 
after the completion of LD-CCRT. SIR-sphere® Y-90 resin 
microspheres (Sirtex Medical, North Sydney, Australia) with 
a total infused radiation activity of 2.5 gigabecquerel was 
infused via the right hepatic artery. The calculated lung dose 
was 17.9. 
Post-treatment CT and MRI were performed sequentially 
(Fig. 3). AFP and PIVKA-II had decreased to normal levels. 
Both radiologic and biological CR was confirmed at 
3 months post-TARE. As an adjuvant therapy, adoptive cell 
transfer (ACT) therapy using Immunecell-LC® (Green cross 
cell, Yongin, Korea) injection of (1.0×108)-(2.0×109) autolo-
gous cytokine induced killer cells was performed 7 times in 
the duration of 10 weeks. 
Ten days after the 7th ACT (19 weeks after TARE), the pa-
Figure 2. Technetium-macroaggregated albumin scintigram of the patient revealed 61.59% lung shunt fraction (LSF), before liver-directed 
concurrent chemoradiotherapy (LD-CCRT) (A). Five weeks after LD-CCRT, LSF was decreased to 12.15% (B).
A B
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tient visited the emergency department with complains of 
dyspnea. On physical examination, the patient presented 
with tachypnea and bilateral crackles on pulmonary auscul-
tation, with no signs of heart failure. Chest CT revealed con-
solidations in both lungs with right pleural effusion, consis-
tent with radiation pneumonitis (Fig. 4A). Treatment began 
Figure 3. Follow-up liver dynamic computed tomography (CT) and magnetic resonance imaging (MRI) findings. (A) CT at delayed phase, 3-weeks 
post-liver-directed concurrent chemoradiotherapy: decreased size of the mass in the right lobe with right hepatic vein thrombosis, from 10.5 cm 
to 8 cm. (B) CT at delayed phase, 3-weeks post-transarterial radio-embolization (TARE): markedly decreased tumor vascularity without remarkable 
change of overall size of the treated tumor in the right posterior liver, 7.6 cm. Diffuse parenchymal atrophy of the right liver observed. (C) CT at 
delayed phase, 6-weeks post-TARE: change in post-treatment infarction and markedly decreased attenuation of the right hemiliver. (D) T2 





Figure 4. Chest high-resolution computed tomography images showing bilateral ground glass opacities and interlobular septal thickening at 
19-weeks post-transarterial radio-embolization (A), remnant radiation pneumonitis after 4 months of steroid therapy (B).
A B
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with 125 mg/day of methylprednisolone with a total tapering 
duration of 4 months. The patient’s clinical condition im-
proved with the considerable resolution of radiation pneu-
monitis on CT that was taken 4 months after steroid therapy 
(Fig. 4B). The patient exhibited remarkable pulmonary pa-
renchymal recovery, with no evidence of pulmonary dys-
function or the need for oxygen. 
Fifteen months after CR, follow-up CT showed an approx-
imately 2 cm recurrent tumor with washout in the delayed 
phase at liver S7 (Fig. 5A). TACE using 20 mg of adriamycin 
and lipiodol mixture was performed, and compact lipiodol 
uptake in the recurrent tumor at liver S7 was found at 
3 weeks post-TACE CT, without new or residual tumor 
(Fig. 5B). The patient remains alive with no remnant or re-
current tumors in the liver. The clinical course is described 
in Fig. 6 according to the treatment modalities and changes 
in tumor markers.
DISCUSSION
In this study, we present a case of a large single HCC treat-
ed with two types of LRTs, including LD-CCRT and TARE. 
Figure 5. Findings on liver dynamic computed tomography images. Newly noted recurrent tumor at liver S7, about 2 cm at 19-months post-
transarterial radio-embolization (A). Compact lipiodol uptake in the recurrent tumor at liver S7 without new or residual tumor, 1-month post-
transarterial chemoembolization (B).
A B
Figure 6. Cinical course of the patient with alpha-fetoprotein (AFP), prothrombin induced by vitamin K absence (PIVKA)-II. A biological complete 
response was achieved at 3-weeks post-transarterial radio-embolization. CCRT, concurrent chemoradiotherapy; TARE, transarterial radio-
embolization; ACT, adoptive cell transfer; TACE, transarterial chemoembolization.
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We did not consider surgical resection as a treatment option 
because both high serum AFP levels and major vascular inva-
sion are major predictors of poor survival after surgical re-
section in patients.11,12 
According to current practice guidelines, systemic sorafenib 
or lenvatinib is the first-line therapeutic option for advanced 
HCC.5 However, the present patient had neither underlying 
hepatitis nor cirrhosis, and exhibited preserved liver func-
tion; we therefore thought that palliative treatment alone 
might be a suboptimal option for the patient. We considered 
TARE as the first option of LRT. Some studies have suggest-
ed that TARE is more advantageous than sorafenib in PVT. 
Edeline et al.13 showed a median OS of 26.2 versus 8.7 months 
in patients treated with TARE versus sorafenib. However, 
TARE is contraindicated in patients with a high LSF, primar-
ily due to radiation-induced lung injury.10 Considering that 
20% of LSF is the generally accepted limit of SIR-Spheres, 
our patient could not be a candidate for TARE owing to a 
high LSF of 61.59%. 
To date, there have been several studies to manage high 
LSF in patients undergoing TARE, including bland emboli-
zation or chemoembolization, hepatic vein occlusion bal-
loons, low-dose radio-embolization, and chemotherapy.14,15 
One of suggested mechanisms about chemotherapy is that 
“normalizing” the tumor vascularity with chemotherapy not 
only reduces the abnormal vessels including shunts but also 
increases blood flow to the tumors, making tumor more re-
sponsive to TARE.14 Since LD-CCRT includes both local RT 
and concurrent hepatic arterial infusion chemotherapy, LSF 
might be effectively decreased. Furthermore, tumor shrink-
age through LD-CCRT has also been reported, which could 
prolong survival in patients with advanced but liver-confined 
HCC.16 LD-CCRT may be adopted as a proper option in this 
case. 
Liver dynamic CT at 3 weeks after LD-CCRT showed that 
the mass had decreased from 10.5 cm to 8 cm. We excluded 
surgical resection as a subsequent treatment option because 
PV thrombosis could not be excluded on follow-up CT. Re-
garding TARE, lung scintigraphy was performed again, 
which showed a 12.15% LSF. TARE was performed 1 week 
after lung scintigraphy because delaying TARE could increase 
the LSF.
Despite a reduced LSF, radiation pneumonitis occurred 
19 weeks post-TARE. Radiation pneumonitis often occurs as 
a post-TARE complication because the lung tissue is suscep-
tible to radiation damage.17 Leung et al.17 reported that 55.6% 
(5 out of 9) of patients with lung shunting greater than 13% 
developed radiation pneumonitis. Even though the LSF was 
reduced to 12.15% by LD-CCRT, there is a possibility that 
new collaterals and arteriovenous shunts opened up between 
lung scintigraphy and TARE. Our patient was able to return 
to his daily life after 4 months of steroid therapy.
We found an optimal response on CT and planned con-
secutive systemic therapy. So far, there has been no proven 
benefit for molecular target agents such as sorafenib to re-
duce recurrence after achievement of CR.18 Meanwhile, addi-
tional immunotherapeutic approaches, such as ACT, have 
been actively researched as a combination modality with 
other systemic therapies or LRT.19 ACT improves the quality 
and quantity of anti-cancer cells and reduces the immune 
system’s tolerance to cancer cells. Previous studies have 
shown that adoptive immunotherapy could lower the fre-
quency of recurrence and improve recurrence-free outcomes 
after surgery or radiofrequency ablation for HCC.20 ATC 
therapy was the appropriate option in this case. Although a 
2 cm-sized HCC had recurred once, the patient had been in 
a healthy state without HCC until 30 months after diagnosis.
In conclusion, we described a case of advanced-stage HCC 
that was successfully treated with a combination therapy of 
LRT and adjuvant systemic therapy. Thus, LD-CCRT and 
sequential TARE may be a useful treatment option for select-
ed patients with advanced-stage HCC. Although current 
guidelines for advanced HCC still favor systemic agents as a 
standard of care, various studies on the role of active LRTs 
have been in progress for advanced HCC with preserved liver 
function and without extrahepatic involvement. Further re-
search for sub-classification of advanced-stage HCC, where 
active LRTs would be more advantageous than systemic 
therapy alone is necessary.
Conflicts of Interest
The authors declare no competing interests.
103
 Minho Noh, et al.
LD-CCRT and TARE in advanced HCC
http://www.livercancer.or.kr
REFERENCES
1. Chan SL, Chong CCN, Chan AWH, Poon DMC, Chok KS. Man-
agement of hepatocellular carcinoma with portal vein tumor 
thrombosis: review and update at 2016. World J Gastroenterol 
2016;22:7289-7300.
2. Díaz-González Á, Reig M, Bruix J. Treatment of hepatocellular car-
cinoma. Dig Dis 2016;34:597-602.
3. Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Ya-
maguchi K, et al. Sorafenib versus hepatic arterial infusion che-
motherapy as initial treatment for hepatocellular carcinoma with 
advanced portal vein tumor thrombosis. Liver Cancer 2017;6:275-
286.
4. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy 
and safety of transarterial chemoembolization plus external beam 
radiotherapy vs sorafenib in hepatocellular carcinoma with macro-
scopic vascular invasion: a randomized clinical trial. JAMA Oncol 
2018;4:661-669.
5. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wede-
meyer H, Pratt D, et al. Tremelimumab in combination with abla-
tion in patients with advanced hepatocellular carcinoma. J Hepatol 
2017;66:545-551.
6. Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. 
Challenges of advanced hepatocellular carcinoma. World J Gastro-
enterol 2016;22:7645-7659.
7. Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, et al. Ef-
ficacy and safety of liver-directed concurrent chemoradiotherapy 
and sequential sorafenib for advanced hepatocellular carci-
noma: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 
2020;107:106-115.
8. Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, et al. Appraisal 
of long-term outcomes of liver-directed concurrent chemoradio-
therapy for hepatocellular carcinoma with major portal vein inva-
sion. J Hepatocell Carcinoma 2020;7:403-412.
9. Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Insti-
tutional decision to adopt Y90 as primary treatment for hepatocel-
lular carcinoma informed by a 1,000-patient 15-year experience. 
Hepatology 2018;68:1429-1440.
10. Sangro B, Gardini AC. Radioembolisation in hepatocellular car-
cinoma: principles of management. In: Cross T, Palmer DH, eds. 
Liver cancers: from mechanisms to management. Cham: Springer 
International Publishing, 2019:139-152.
11. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, et al. 
Critical appraisal of the clinical and pathologic predictors of sur-
vival after resection of large hepatocellular carcinoma. Arch Surg 
2005;140:450-457; discussion 457-458.
12. Hermanek P, Hendson DE, Hutter RVP, Sobin LH. TNM supplement 
1993: a commentary on uniform use. Heidelberg: Springer-Verlag; 
1993:1-142.
13. Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, 
Guillygomarc’h A, et al. Selective internal radiation therapy com-
pared with sorafenib for hepatocellular carcinoma with portal vein 
thrombosis. Eur J Nucl Med Mol Imaging 2016;43:635-643.
14. Schiro BJ, Amour ES, Harnain C, Gandhi RT. Management of high 
hepatopulmonary shunts in the setting of Y90 radioembolization. 
Tech Vasc Interv Radiol 2019;22:58-62.
15. Theysohn JM, Schlaak JF, Müller S, Ertle J, Schlosser TW, Bockisch 
A, et al. Selective internal radiation therapy of hepatocellular carci-
noma: potential hepatopulmonary shunt reduction after sorafenib 
administration. J Vasc Interv Radiol 2012;23:949-952.
16. Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors 
related to recurrence after hepatic arterial concurrent chemoradio-
therapy for advanced but liver-confined hepatocellular carcinoma. 
J Radiat Res 2013;54:1069-1077.
17. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. 
Radiation pneumonitis after selective internal radiation treatment 
with intraarterial 90Yttrium-microspheres for inoperable hepatic 
tumors. Int J Radiat Oncol Biol Phys 1995;33:919-924.
18. Mokdad AA, Singal AG, Yopp AC. Advances in local and systemic 
therapies for hepatocellular cancer. Curr Oncol Rep 2016;18:9.
19. Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackov-
ic D, et al. The promise of adoptive cellular immunotherapies in 
hepatocellular carcinoma. Oncoimmunology 2020;9:1673129.
20. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Ya-
mamoto J, et al. Adoptive immunotherapy to lower postsurgical 
recurrence rates of hepatocellular carcinoma: a randomised trial. 
Lancet 2000;356:802-807.
